VCEL Vericel Corporation

Aastrom Biosciences' CEO to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference ANN ARBOR, Mich., April 29 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) today announced that R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference. The conference will be held May 4- 5th, at the InterContinental Hotel in Paris, France. Dr. Armstrong will present in the Salon Imperial at 7:00 a.m. (Eastern Time), or 1:00 p.m. (Paris), on Wednesday, May 4th. Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. Rodman employs dedicated, experienced, and talented professionals within its equity research, corporate finance, and sales & trading divisions. A live webcast of Aastrom's presentation can be accessed by logging onto the web at http://www.wsw.com/webcast/rrshq5/astm/. An archived replay of the presentation will also be available for 90 days after the conference, at the same site. For more information about the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference, please visit Rodman & Renshaw's website at http://www.rodmanandrenshaw.com/. About Aastrom Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's strategic position in the tissue regeneration sector is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells, and the AastromReplicell(R) System, an industry-unique automated cell production platform used to produce cells for clinical use. TRCs are the core component of the products Aastrom is developing for severe bone fractures, ischemic vascular disease, jaw reconstruction and spine fusion, with Phase I/II level clinical trials active in the U.S. and EU for some of these indications. For more information, visit Aastrom's website at http://www.aastrom.com/. This document contains forward-looking statements, including without limitation, statements regarding product development objectives, market development plans, and potential advantages and applications of the AastromReplicell(R) System and related products, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "plans," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward- looking statements. Among the factors that may result in differences are the results obtained from clinical trial activities, regulatory approval requirements, and the availability of resources. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10- K and other filings with the Securities and Exchange Commission. CONTACTS: Kris M. Maly or Kevin McGrath Becky Anderson Cameron Associates Investor Relations Department Phone: (212) 245-4577 Aastrom Biosciences, Inc. Phone: (734) 930-5777 DATASOURCE: Aastrom Biosciences, Inc. CONTACT: Kris M. Maly or Becky Anderson, Investor Relations Department, +1-734-930-5777, both of Aastrom Biosciences, Inc.; or Kevin McGrath of Cameron Associates, +1-212-245-4577 Web site: http://www.aastrom.com/ http://www.wsw.com/webcast/rrshq5/astm http://www.rodmanandrenshaw.com/

Copyright